Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003312 · ClinicalTrials.gov registry record · Phase 2
Brachytherapy in Treating Patients With Prostate Cancer
A Phase 2 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 95
- Enrollment target
NCT00003312 is a Phase 2 study that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 95 participants.
The verdict
NCT00003312, a Phase 2 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 95 participants
- Enrollment target
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy through seeds implanted into the prostate may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of brachytherapy in treating patients with stage I or stage II prostate cancer.
Interventions
- RADIATION iodine I 125
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 1998-09 |
| Est. Completion | 2013-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003312
The ClinicalTrials.gov registry entry for NCT00003312 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which iodine I 125 is the first listed.
NCT00003312 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003312 about?
NCT00003312 is a clinical study titled "Brachytherapy in Treating Patients With Prostate Cancer". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy through seeds implanted into the prostate may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of brachytherapy in treating patients with stage I or stage II prostate cancer...
What is the current status of trial NCT00003312?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 95 participants. The study started on 1998-09. Estimated completion is 2013-11.
What interventions are being tested in trial NCT00003312?
The interventions under investigation include: iodine I 125 (RADIATION).
Who is sponsoring clinical trial NCT00003312?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.